Tango Therapeutics, Inc. (TNGX)
21.73
-0.98
(-4.32%)
USD |
NASDAQ |
Nov 20, 16:00
21.74
0.00 (0.00%)
After-Hours: 20:00
Tango Therapeutics Enterprise Value : 2.731B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 2.731B |
| November 19, 2026 | 2.896B |
| November 18, 2026 | 2.758B |
| November 17, 2026 | 2.795B |
| November 16, 2026 | 3.143B |
| November 13, 2026 | 3.368B |
| November 12, 2026 | 3.258B |
| November 11, 2026 | 3.407B |
| November 10, 2026 | 3.165B |
| November 09, 2026 | 2.901B |
| November 06, 2026 | 2.692B |
| November 05, 2026 | 2.585B |
| November 04, 2026 | 2.976B |
| November 03, 2026 | 2.974B |
| November 02, 2026 | 2.736B |
| October 30, 2026 | 2.898B |
| October 29, 2026 | 2.866B |
| October 28, 2026 | 2.815B |
| October 27, 2026 | 2.927B |
| October 26, 2026 | 2.809B |
| October 23, 2026 | 3.003B |
| October 22, 2026 | 3.780B |
| October 21, 2026 | 3.619B |
| October 20, 2026 | 3.326B |
| October 19, 2026 | 3.035B |
| Date | Value |
|---|---|
| October 16, 2026 | 2.783B |
| October 15, 2026 | 2.895B |
| October 14, 2026 | 2.808B |
| October 13, 2026 | 2.813B |
| October 12, 2026 | 3.143B |
| October 09, 2026 | 3.082B |
| October 08, 2026 | 2.873B |
| October 07, 2026 | 2.747B |
| October 06, 2026 | 2.759B |
| October 05, 2026 | 2.959B |
| October 02, 2026 | 2.986B |
| October 01, 2026 | 3.191B |
| September 30, 2026 | 3.275B |
| September 29, 2026 | 3.130B |
| September 28, 2026 | 3.110B |
| September 25, 2026 | 3.214B |
| September 24, 2026 | 3.165B |
| September 23, 2026 | 3.135B |
| September 22, 2026 | 3.317B |
| September 21, 2026 | 2.778B |
| September 18, 2026 | 2.680B |
| September 17, 2026 | 2.973B |
| September 16, 2026 | 2.950B |
| September 15, 2026 | 3.041B |
| September 14, 2026 | 3.150B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.362B |
| Erasca, Inc. | 4.166B |
| NovelStem International Corp. | 1.983M |
| Brainstorm Cell Therapeutics, Inc. | 12.51M |
| Summit Therapeutics, Inc. | 7.347B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -68.39M |
| Total Expenses (Quarterly) | 68.39M |
| EPS Diluted (Quarterly) | -0.3932 |
| Earnings Yield | -6.32% |
| Normalized Earnings Yield | -6.323 |